Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Launched by ADICET THERAPEUTICS · Jun 2, 2021

Keywords

ClinConnect Summary

This is a non-therapeutic, multi-center, long-term follow-up (LTFU) study of subjects who received an Adicet Bio allogeneic γδ CAR T cell product that has been genetically engineered to express the anti-CD20 CAR by transduction with a self-inactivating, replication incompetent gamma retroviral vector. The period of follow-up is 15 years after the administration of the γδ CAR T cell product.

The study involves up to 15 years post-infusion monitoring of subjects who have been exposed to a genetically engineered CAR in Adicet Bio clinical studies. Upon early termination/discontinuation or com...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients who received any Adicet allogeneic CAR T investigational product and have either completed the core treatment protocol or have discontinued early
• • All patients who are willing and able to adhere to the study visit schedule and other protocol requirements.
• • Capable of giving signed informed consent which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and protocol
• Exclusion Criteria:
• • There are no specific exclusion criteria for this study